Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9297011 KIF5B-RET fusion molecules and uses thereof

Patent 9297011 was granted and assigned to Foundation Medicine on March, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Foundation Medicine

Current Assignee

Foundation Medicine

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9297011

Patent Inventor Names

Alexander N. Parker0

Doron Lipson0

Matthew J. Hawryluk0

Philip James Stephens0

Sean R. Downing0

Date of Patent

March 29, 2016

Patent Application Number

14187280

Date Filed

February 23, 2014

Patent Citations Received

‌

US Patent 11964988 Fused heterocyclic compounds as RET kinase inhibitors

‌

US Patent 11963958 RET inhibitor for use in treating cancer having a RET alteration

‌

US Patent 11998545 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

‌

US Patent 11872192 RET inhibitor for use in treating cancer having a RET alteration

‌

US Patent 11851434 Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Patent Primary Examiner

‌

James D. Anderson

Patent abstract

Novel RET fusion molecules and uses are disclosed.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9297011 KIF5B-RET fusion molecules and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API